Skip to main content
Top
Published in: European Radiology 11/2020

01-11-2020 | Magnetic Resonance Imaging | Hepatobiliary-Pancreas

Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study

Authors: Shintaro Ichikawa, Hiroyoshi Isoda, Tatsuya Shimizu, Daiki Tamada, Kojiro Taura, Kaori Togashi, Hiroshi Onishi, Utaroh Motosugi

Published in: European Radiology | Issue 11/2020

Login to get access

Abstract

Objectives

To determine imaging hallmarks for distinguishing intrahepatic mass-forming biliary carcinomas (IMBCs) from hepatocellular carcinoma (HCC) and to validate their diagnostic ability using Bayesian statistics.

Methods

Study 1 retrospectively identified clinical and imaging hallmarks that distinguish IMBCs (n = 41) from HCC (n = 247) using computed tomography (CT) and magnetic resonance imaging (MRI). Study 2 retrospectively assessed the diagnostic ability of these hallmarks to distinguish IMBCs (n = 37) from HCC (n = 111) using Bayesian statistics with images obtained from a different institution. We also assessed the diagnostic ability of the hallmarks in the patient subgroup with high diagnostic confidence (≥ 80% of post-test probability). Two radiologists independently evaluated the imaging findings in studies 1 and 2.

Results

In study 1, arterial phase peritumoral parenchymal enhancement on CT/MRI, delayed enhancement on CT/MRI, diffusion-weighted imaging peripheral hyperintensity, and bile duct dilatation were hallmarks indicating IMBCs, whereas chronic liver disease, non-rim arterial phase hyperenhancement on CT/MRI, enhancing capsule on CT/MRI, and opposed-phase signal drop were hallmarks indicating HCC (p = 0.001–0.04). In study 2, Bayesian statistics-based post-test probability combining all hallmark features had a diagnostic accuracy of 89.2% (132/148) in distinguishing IMBCs from HCC for both readers. In the high diagnostic confidence subgroup (n = 120 and n = 124 for readers 1 and 2, respectively), the accuracy improved (95.0% (114/120) and 93.5% (116/124) for readers 1 and 2, respectively).

Conclusions

Combined interpretation of CT and MRI to identify hallmark features is useful in discriminating IMBCs from HCCs. High post-test probability by Bayesian statistics allows for a more reliable non-invasive diagnosis.

Key Points

• Combined interpretation of CT and MRI to identify hallmark features was useful in discriminating intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma.
• Bayesian method-based post-test probability combining all hallmark features determined in study 1 showed high (> 90%) sensitivity and specificity for distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma.
• If the post-test probability or the confidence was ≥ 80% when combining the imaging features of CT and MRI, the high specificity of > 95% was achieved without any loss of sensitivity to distinguish hepatocellular carcinoma from intrahepatic mass-forming biliary carcinomas.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chinchilla-López P, Aguilar-Olivos NE, García-Gómez J et al (2017) Prevalence, risk factors, and survival of patients with intrahepatic cholangiocarcinoma. Ann Hepatol 16:565–568CrossRef Chinchilla-López P, Aguilar-Olivos NE, García-Gómez J et al (2017) Prevalence, risk factors, and survival of patients with intrahepatic cholangiocarcinoma. Ann Hepatol 16:565–568CrossRef
2.
go back to reference Massarweh NN, El-Serag HB (2017) Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control 24:1073274817729245CrossRef Massarweh NN, El-Serag HB (2017) Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control 24:1073274817729245CrossRef
3.
go back to reference Nakanuma Y, Kakuda Y (2015) Pathologic classification of cholangiocarcinoma: new concepts. Best Pract Res Clin Gastroenterol 29:277–293CrossRef Nakanuma Y, Kakuda Y (2015) Pathologic classification of cholangiocarcinoma: new concepts. Best Pract Res Clin Gastroenterol 29:277–293CrossRef
4.
go back to reference Aishima S, Oda Y (2015) Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary Pancreat Sci 22:94–100CrossRef Aishima S, Oda Y (2015) Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary Pancreat Sci 22:94–100CrossRef
5.
go back to reference Nagtegaal ID, Odze RD, Klimstra D et al (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76:182–188CrossRef Nagtegaal ID, Odze RD, Klimstra D et al (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76:182–188CrossRef
6.
go back to reference Ariizumi S, Yamamoto M (2015) Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis. Surg Today 45:682–687CrossRef Ariizumi S, Yamamoto M (2015) Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis. Surg Today 45:682–687CrossRef
7.
go back to reference Gera S, Ettel M, Acosta-Gonzalez G, Xu R (2017) Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma. World J Hepatol 9:300–309CrossRef Gera S, Ettel M, Acosta-Gonzalez G, Xu R (2017) Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma. World J Hepatol 9:300–309CrossRef
8.
go back to reference Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750CrossRef Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750CrossRef
9.
go back to reference Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH (2019) LI-RADS version 2017 versus version 2018: diagnosis of hepatocellular carcinoma on gadoxetate disodium-enhanced MRI. Radiology 292:655–663CrossRef Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH (2019) LI-RADS version 2017 versus version 2018: diagnosis of hepatocellular carcinoma on gadoxetate disodium-enhanced MRI. Radiology 292:655–663CrossRef
10.
go back to reference Esposito A, Buscarino V, Raciti D et al (2020) Characterization of liver nodules in patients with chronic liver disease by MRI: performance of the Liver Imaging Reporting and Data System (LI-RADS v.2018) scale and its comparison with the Likert scale. Radiol Med 125:15–23CrossRef Esposito A, Buscarino V, Raciti D et al (2020) Characterization of liver nodules in patients with chronic liver disease by MRI: performance of the Liver Imaging Reporting and Data System (LI-RADS v.2018) scale and its comparison with the Likert scale. Radiol Med 125:15–23CrossRef
11.
go back to reference Chen N, Motosugi U, Morisaka H et al (2016) Added value of a gadoxetic acid-enhanced hepatocyte-phase image to the LI-RADS system for diagnosing hepatocellular carcinoma. Magn Reson Med Sci 15:49–59CrossRef Chen N, Motosugi U, Morisaka H et al (2016) Added value of a gadoxetic acid-enhanced hepatocyte-phase image to the LI-RADS system for diagnosing hepatocellular carcinoma. Magn Reson Med Sci 15:49–59CrossRef
12.
go back to reference Asato N, Tsurusaki M, Sofue K et al (2017) Comparison of gadoxetic acid-enhanced dynamic MR imaging and contrast-enhanced computed tomography for preoperative evaluation of colorectal liver metastases. Jpn J Radiol 35:197–205CrossRef Asato N, Tsurusaki M, Sofue K et al (2017) Comparison of gadoxetic acid-enhanced dynamic MR imaging and contrast-enhanced computed tomography for preoperative evaluation of colorectal liver metastases. Jpn J Radiol 35:197–205CrossRef
13.
go back to reference Moon JY, Kim SH, Choi SY, Hwang JA, Lee JE, Lee J (2018) Differentiating malignant from benign hyperintense nodules on unenhanced T1-weighted images in patients with chronic liver disease: using gadoxetic acid-enhanced and diffusion-weighted MR imaging. Jpn J Radiol 36:489–499CrossRef Moon JY, Kim SH, Choi SY, Hwang JA, Lee JE, Lee J (2018) Differentiating malignant from benign hyperintense nodules on unenhanced T1-weighted images in patients with chronic liver disease: using gadoxetic acid-enhanced and diffusion-weighted MR imaging. Jpn J Radiol 36:489–499CrossRef
14.
go back to reference Li J, Wang J, Lei L, Yuan G, He S (2019) The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies. Eur Radiol 29:6519–6528CrossRef Li J, Wang J, Lei L, Yuan G, He S (2019) The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies. Eur Radiol 29:6519–6528CrossRef
15.
go back to reference Li J, Li X, Weng J et al (2018) Gd-EOB-DTPA dynamic contrast-enhanced magnetic resonance imaging is more effective than enhanced 64-slice CT for the detection of small lesions in patients with hepatocellular carcinoma. Medicine (Baltimore) 97:e13964 Li J, Li X, Weng J et al (2018) Gd-EOB-DTPA dynamic contrast-enhanced magnetic resonance imaging is more effective than enhanced 64-slice CT for the detection of small lesions in patients with hepatocellular carcinoma. Medicine (Baltimore) 97:e13964
16.
go back to reference Liu X, Jiang H, Chen J, Zhou Y, Huang Z, Song B (2017) Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis. Liver Transpl 23:1505–1518CrossRef Liu X, Jiang H, Chen J, Zhou Y, Huang Z, Song B (2017) Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis. Liver Transpl 23:1505–1518CrossRef
17.
go back to reference Joo I, Lee JM, Lee DH, Jeon JH, Han JK (2019) Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 29:1724–1732CrossRef Joo I, Lee JM, Lee DH, Jeon JH, Han JK (2019) Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 29:1724–1732CrossRef
18.
go back to reference Kim DH, Choi SH, Kim SY, Kim MJ, Lee SS, Byun JH (2019) Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: value of washout in transitional and hepatobiliary phases. Radiology 291:651–657CrossRef Kim DH, Choi SH, Kim SY, Kim MJ, Lee SS, Byun JH (2019) Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: value of washout in transitional and hepatobiliary phases. Radiology 291:651–657CrossRef
19.
go back to reference Vernuccio F, Cannella R, Meyer M et al (2019) LI-RADS: diagnostic performance of hepatobiliary phase hypointensity and major imaging features of LR-3 and LR-4 lesions measuring 10-19 mm with arterial phase hyperenhancement. AJR Am J Roentgenol 213:W57–W65CrossRef Vernuccio F, Cannella R, Meyer M et al (2019) LI-RADS: diagnostic performance of hepatobiliary phase hypointensity and major imaging features of LR-3 and LR-4 lesions measuring 10-19 mm with arterial phase hyperenhancement. AJR Am J Roentgenol 213:W57–W65CrossRef
20.
go back to reference Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 149:565–574CrossRef Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 149:565–574CrossRef
21.
go back to reference Adam SZ, Parthasarathy S, Miller FH (2015) Intrahepatic cholangiocarcinomas mimicking other lesions. Abdom Imaging 40:2345–2354CrossRef Adam SZ, Parthasarathy S, Miller FH (2015) Intrahepatic cholangiocarcinomas mimicking other lesions. Abdom Imaging 40:2345–2354CrossRef
22.
go back to reference Murakami T, Tsurusaki M (2014) Hypervascular benign and malignant liver tumors that require differentiation from hepatocellular carcinoma: key points of imaging diagnosis. Liver Cancer 3:85–96CrossRef Murakami T, Tsurusaki M (2014) Hypervascular benign and malignant liver tumors that require differentiation from hepatocellular carcinoma: key points of imaging diagnosis. Liver Cancer 3:85–96CrossRef
23.
go back to reference Kim R, Lee JM, Shin CI et al (2016) Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging. Eur Radiol 26:1808–1817CrossRef Kim R, Lee JM, Shin CI et al (2016) Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging. Eur Radiol 26:1808–1817CrossRef
24.
go back to reference Choi SH, Lee SS, Kim SY et al (2017) Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT. Radiology 282:771–781CrossRef Choi SH, Lee SS, Kim SY et al (2017) Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT. Radiology 282:771–781CrossRef
25.
go back to reference Sheng RF, Zeng MS, Rao SX, Ji Y, Chen LL (2014) MRI of small intrahepatic mass-forming cholangiocarcinoma and atypical small hepatocellular carcinoma (</=3 cm) with cirrhosis and chronic viral hepatitis: a comparative study. Clin Imaging 38:265–272CrossRef Sheng RF, Zeng MS, Rao SX, Ji Y, Chen LL (2014) MRI of small intrahepatic mass-forming cholangiocarcinoma and atypical small hepatocellular carcinoma (</=3 cm) with cirrhosis and chronic viral hepatitis: a comparative study. Clin Imaging 38:265–272CrossRef
26.
go back to reference Kim SA, Lee JM, Lee KB et al (2011) Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern--correlation with clinicopathologic findings. Radiology 260:148–157CrossRef Kim SA, Lee JM, Lee KB et al (2011) Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern--correlation with clinicopathologic findings. Radiology 260:148–157CrossRef
27.
go back to reference Park HJ, Kim YK, Park MJ, Lee WJ (2013) Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 38:793–801CrossRef Park HJ, Kim YK, Park MJ, Lee WJ (2013) Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 38:793–801CrossRef
28.
go back to reference Haradome H, Unno T, Morisaka H et al (2017) Gadoxetic acid disodium-enhanced MR imaging of cholangiolocellular carcinoma of the liver: imaging characteristics and histopathological correlations. Eur Radiol 27:4461–4471CrossRef Haradome H, Unno T, Morisaka H et al (2017) Gadoxetic acid disodium-enhanced MR imaging of cholangiolocellular carcinoma of the liver: imaging characteristics and histopathological correlations. Eur Radiol 27:4461–4471CrossRef
29.
go back to reference McHugh ML (2012) Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 22:276–282CrossRef McHugh ML (2012) Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 22:276–282CrossRef
30.
go back to reference Jeong HT, Kim MJ, Chung YE, Choi JY, Park YN, Kim KW (2013) Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation. AJR Am J Roentgenol 201:W603–W611CrossRef Jeong HT, Kim MJ, Chung YE, Choi JY, Park YN, Kim KW (2013) Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation. AJR Am J Roentgenol 201:W603–W611CrossRef
31.
go back to reference Kudo M, Izumi N, Ichida T et al (2016) Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res 46:372–390CrossRef Kudo M, Izumi N, Ichida T et al (2016) Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res 46:372–390CrossRef
Metadata
Title
Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study
Authors
Shintaro Ichikawa
Hiroyoshi Isoda
Tatsuya Shimizu
Daiki Tamada
Kojiro Taura
Kaori Togashi
Hiroshi Onishi
Utaroh Motosugi
Publication date
01-11-2020
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 11/2020
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-020-06972-w

Other articles of this Issue 11/2020

European Radiology 11/2020 Go to the issue